6 October 2025
Incanthera plc
("Incanthera" or the "Company")
INVESTOR PRESENTATION
PROACTIVE BIOTECH ONE2ONE INVESTOR FORUM
9 OCTOBER 2025
Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, announces that it will be presenting at the Proactive Investor Forum in
Incanthera will be delivering a presentation, which will not contain any inside information, and will be made available on its website, www.incanthera.com.
In order to register for the event, please use the attached link: Proactive One2One Investor Forum - Thursday 9th October Tickets, Thu 9 Oct 2025 at 18:00 | Eventbrite
RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.
For further information please contact:
Incanthera plc:
|
Tim McCarthy, Chairman tim.mccarthy@incanthera.com
Simon Ward, Chief Executive Officer simon.ward@incanthera.com
Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
|
|
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney |
+44 (0) 20 3650/51 |
Notes to Editors
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
